Last reviewed · How we verify
NCT03922269: TIME
Trans People Living With HIV Throughout Europe
trial in HIV Infections in 200 participants. Completed in 17 December 2025.
17 December 2025
Quick facts
| Lead sponsor | Chelsea and Westminster NHS Foundation Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 11 October 2019 |
| Primary completion | 17 December 2025 |
| Estimated completion | 17 December 2025 |
| Sites | 4 locations across Italy, United Kingdom |
Conditions studied
- HIV Infections — all drugs for HIV Infections →
- Gender Identity — all drugs for Gender Identity →
- Human Immunodeficiency Virus — all drugs for Human Immunodeficiency Virus →
Sponsor
Chelsea and Westminster NHS Foundation Trust
Who can join
18 and older, any sex, with HIV Infections or Gender Identity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The project will study a European cohort of individuals identifying themselves as transgender or non-binary and living with HIV. The study will collect both qualitative data on this cohort and clinical data over an 18 month period. The study will investigate the success of HIV treatment for this cohort through the primary outcome measure of HIV viral load recorded in routine blood tests. The results from this study will assist in informing future HIV treatment guidelines on the monitoring of HIV infection in transgender and non-binary individuals and assisting in the design of future interventional studies within this population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03922269
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for HIV Infections
Currently open trials in the same condition.
- NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
- NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
- NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting
Other Chelsea and Westminster NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07124390 — Electroacupuncture as a Treatment for Refractory Overactive Bladder · NA · not yet recruiting
- NCT07202221 — Spoken Animation for Labour Epidural · NA · not yet recruiting
- NCT06775769 — Endometrioma Sclerotherapy and Ovarian Preservation · NA · recruiting
- NCT05289986 — The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients · Phase 4 · terminated
- NCT06118632 — Physiological and Environmental Data in a Remote Setting to Predict Exacerbation Events in Patients With Chronic Obstruc · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03922269 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chelsea and Westminster NHS Foundation Trust
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03922269.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing